EPI Health
  • Home
  • About EPI Health
    • Visions & Values
    • Leadership
    • Careers
  • Products
    • Rhofade
    • Minolira
    • Cloderm
    • Sitavig
    • Nuvail
    • Bensal
    • Bionect
  • News
  • Resources
    • Rhofade
  • Contact
Select Page

EPI Health Expands Solid Payor Coverage on Rhofade

by EPI Health | Nov 4, 2020 | Press Release

  NEWS PROVIDED BY EPI Health, LLC November 4, 2020   The formulary at Express Scripts and other major PBMs have expanded coverage to include Rhofade® and other EPI Health Products, bringing coverage to over 145 million US Commercial lives.   Rhofade®...

EPI Health Announces Rhofade® (oxymetazoline hydrochloride) cream, 1% is now covered on the Express Scripts National Preferred Formulary

by EPI Health | Sep 20, 2020 | Press Release

  Express Scripts National Preferred Formulary covers approximately 24 million lives — Rhofade® is the only FDA-approved alpha 1 agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults   CHARLESTON,...

MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US

by EPI Health | Aug 26, 2020 | Press Release

Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US   WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in...

EPI Health, LLC Acquires Worldwide Rights to RHOFADE® from Aclaris Therapeutics, Inc.

by EPI Health | Dec 9, 2019 | Press Release

  NEWS PROVIDED BY EPI Health, LLC October 14, 2019, 08:00 ET CHARLESTON, SC, October 14, 2019 /PRNewswire/ — EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists, today announced...

EPI Health, LLC Appoints Brett Fair as Vice President of Commercial Operations and Strategy

by EPI Health | Sep 17, 2019 | Press Release

CHARLESTON, SC / ACCESSWIRE / September 17, 2019 / EPI Health, LLC, a specialty pharmaceutical company focused on acquiring, developing and marketing prescription medical dermatological products, today announced the appointment of Brett Fair as Vice President of...
« Older Entries

Recent Posts

  • EPI Health Expands Solid Payor Coverage on Rhofade
  • EPI Health Announces Rhofade® (oxymetazoline hydrochloride) cream, 1% is now covered on the Express Scripts National Preferred Formulary
  • MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US
  • EPI Health, LLC Acquires Worldwide Rights to RHOFADE® from Aclaris Therapeutics, Inc.
  • EPI Health, LLC Appoints Brett Fair as Vice President of Commercial Operations and Strategy

Recent Comments

    Prescription Dermatology Products

    Business Development

    Leadership

    Social Responsibility

    Careers

    General Inquiries

    Contact Us

    Directions / Map

    Copyright 2020 | All Rights Reserved | Website Design by King & Columbus